Sfoglia per Autore
Folfoxiri improves survival compared to folfiri as first-line treatment of metastatic colorectal cancer (MCRC): updated results of a randomized phase III study by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
2006-01-01 Masi, G.; Barbara, C.; Brunetti, I.; Pfanner, E.; Murr, R.; Ricci, S.; Benedetti, G.; Crinò, L.; Evangelista, W.; Berretto, O.; Picone, V.; Cortesi, E.; Vitello, S.; Chiara, S.; Granetto, C.; Merlano, M.; Fioretto, L.; Orlandini, C.; Andreuccetti, M.; Falcone, Alfredo
Biweekly irinotecan, oxaliplatin, and infusional 5-FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized, phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
2006-01-01 Falcone, Alfredo; Masi, G.; Murr, R.; Benedetti, G.; Bertetto, O.; Ferraldeschi, R.; Chiara, S.; Granetto, C.; Alabiso, O.; Ricci, S.
TREATMENT WITH 5FLUOROURACIL/FOLINIC ACID OXALIPLATIN AND IRINOTECAN ENABLES URGICAL RESECTION OF METASTASES IN PATIENTS WITH INITIALLY UNRESECTABLE METASTASTIC COLORECTAL CANCER
2006-01-01 Masi, G; Cupini, S; Marcucci, L; Cerri, E; Loupakis, F; Allegrini, G; Brunetti, Im; Pfanner, E; Viti, M; Goletti, Orlando; Filipponi, Franco; Falcone, Alfredo
Predictive role of a pharmacogenetic profiling in patients with advanced colorectal cancer (ACRC) treated with first-line, 5-fluorouracil/oxaliplatin chemotherapy
2006-01-01 Graziano, F.; Russo, A. M.; Loupakis, F.; Canestrari, E.; Santini, D.; Catalano, V.; Ficarelli, R.; Mari, D.; Bisonni, R.; Masi, G.; Schiavon, G.; Safina, V.; Maltese, P.; Pizzagalli, F.; Giordani, P.; Lippe, P.; Alessandrini, P.; Giustini, L.; Falcone, Alfredo; Tonini, G.; Silva, R. R.; Mattioli, R.; Menichetti, E. T.; Testa, E.; Lai, V.; Magnani, M.
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation
2006-01-01 Allegrini, G; DI PAOLO, Antonello; Cerri, E; Cupini, S; Amatori, F; Masi, G; Danesi, Romano; Marcucci, L; Bocci, Guido; DEL TACCA, M; Falcone, Alfredo
Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by Irinotecan (IR) + 5-FU/LV (IRFL) followed by Docetaxel (T) + 5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): preliminary results of a phase II trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
2006-01-01 Loupakis, F.; Masi, G.; Fontana, E.; Allegrini, G.; Bursi, S.; Barbara, C.; Cerri, E.; Barletta, M. T.; Picone, V.; Mentuccia, L.; Granetto, C.; Fea, E.; Pfanner, E.; Murr, R.; Brunetti, I.; Andreuccetti, M.; Falcone, Alfredo
Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
2007-01-01 Cupini, S.; Bursi, S.; Masi, G.; Loupakis, F.; Barbara, C.; Barletta, M. T.; Baldi, G. G.; Vasile, E.; Fornaro, L.; Petrini, Iacopo; Allegrini, G.; Antonuzzo, A.; DI MARSICO, R.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo
Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (IR) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologico Nord-Ovest (GONO)
2007-01-01 Loupakis, F.; Masi, G.; Bursi, S.; Picone, V.; Mentuccia, L.; Granetto, C.; Fea, E.; Murr, R.; Antonuzzo, A.; Falcone, Alfredo
Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases
2007-01-01 Masi, G.; Bursi, S.; Loupakis, F.; Barbara, C.; Brunetti, I.; Ferraldeschi, R.; Evangelista, W.; Chiara, S.; Granetto, C.; Falcone, Alfredo
The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)
2007-01-01 Masi, G.; Bursi, S.; Loupakis, F.; Barletta, M.; Baldi, G.; Antonuzzo, A.; Sonaglio, C.; Pfanner, E.; Petrini, Iacopo; Falcone, Alfredo
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)
2007-01-01 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; Petrini, Iacopo; Barletta, M. T.; Baldi, G. G.; Falcone, Alfredo
Randomized phase III study of FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) vs FOLFIRI (irinotecan and 5FU/LV) as first-line treatment of metastatic colorectal cancer (MCRC): Subgroup and multivariate analysis
2007-01-01 Falcone, Alfredo; Andreuccetti, M.; Orlandini, C.; Barbara, C.; Benedetti, G.; Evangelista, W.; Picone, V.; Chiara, S.; Granetto, C.; Masi, G.
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
2007-01-01 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G. G.; Barletta, M. T.; Fornaro, L.; Allegrini, G.; Donati, S.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo
Pharmacogenetic profiling for anti-epidermal growth factor receptor (EGFR) therapy in (pts) with refractory advanced colorectal cancer (ACRC)
2007-01-01 Graziano, F.; Ruzzo, A.; Loupakis, F.; Floriani, I.; Canestrari, E.; Santini, D.; Catalano, V.; Torresi, U.; Bisonni, R.; Masi, G.; Schiavon, G.; Andreoni, F.; Maltese, P.; Giustini, L.; Falcone, Alfredo; Tonini, G.; Rulli, E.; Fontana, A.; Mari, D.; Magnani, M.
First-line folfoxiri followed by R0 surgical resection of metastases in unresectable metastatic colorectal cancer (MCRC) patients (pts)
2007-01-01 Masi, G.; Loupakis, F.; Bursi, S.; Barbara, C.; Barletta, M. T.; Baldi, G.; Cupini, S.; Brunetti, I.; Pfanner, E.; Lencioni, M.; DI DONATO, S.; Mentuccia, L.; Fanchini, L.; Sonaglio, C.; Fea, E.; Allegrini, G.; Falcone, Alfredo
Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(MCRC): Updated results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study
2007-01-01 Falcone, Alfredo; Andreuccetti, M.; Ricci, S.; Orlandini, C.; Barbara, C.; Evangelista, W.; Ciuffreda, L.; Cortesi, E.; Ferraldeschi, R.; Chiara, S.; Granetto, C.; Loupakis, F.; Bursi, S.; Allegrini, G.; Masi, G.
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group
2007-01-01 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G.; Barletta, M.; Allegrini, G.; Ricci, S.; Falcone, Alfredo
Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line folfoxiri followed by r0 surgical resection of metastases
2007-01-01 Masi, G.; Bursi, S.; Loupakis, F.; Barletta, M.; Barbara, C.; Vasile, E.; Cupini, S.; Brunetti, I.; Pfanner, E.; DI DONATO, S.; Dauria, G.; Fanchini, L.; Chiara, S.; Granetto, C.; Falcone, Alfredo
Pegfilgrastim to support chop-r chemotherapy administered every 14 days in the patients (pts) with aggressive b-cell non-hodgkin’s lymphoma (NHL)
2007-01-01 Capochiani, E.; Cupini, S.; Loupakis, F.; Vasile, E.; Fontana, A.; Barbara, C.; Bursi, S.; Landi, L.; Coltelli, L.; Safina, V.; Barletta, M. T.; Baldi, G. G.; Giuntini, N.; LO DICO, M.; Mazzoni, E.; Masi, G.; Falcone, Alfredo
Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
2007-01-01 Cupini, S.; Bursi, S.; Masi, G.; Loupakis, F.; Barbara, C.; Fornaro, L.; Allegrini, G.; DI MARSICO, R.; Andreuccetti, M.; Falcone, Alfredo
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Folfoxiri improves survival compared to folfiri as first-line treatment of metastatic colorectal cancer (MCRC): updated results of a randomized phase III study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) | 1-gen-2006 | Masi, G.; Barbara, C.; Brunetti, I.; Pfanner, E.; Murr, R.; Ricci, S.; Benedetti, G.; Crinò, L.; Evangelista, W.; Berretto, O.; Picone, V.; Cortesi, E.; Vitello, S.; Chiara, S.; Granetto, C.; Merlano, M.; Fioretto, L.; Orlandini, C.; Andreuccetti, M.; Falcone, Alfredo | |
| Biweekly irinotecan, oxaliplatin, and infusional 5-FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized, phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) | 1-gen-2006 | Falcone, Alfredo; Masi, G.; Murr, R.; Benedetti, G.; Bertetto, O.; Ferraldeschi, R.; Chiara, S.; Granetto, C.; Alabiso, O.; Ricci, S. | |
| TREATMENT WITH 5FLUOROURACIL/FOLINIC ACID OXALIPLATIN AND IRINOTECAN ENABLES URGICAL RESECTION OF METASTASES IN PATIENTS WITH INITIALLY UNRESECTABLE METASTASTIC COLORECTAL CANCER | 1-gen-2006 | Masi, G; Cupini, S; Marcucci, L; Cerri, E; Loupakis, F; Allegrini, G; Brunetti, Im; Pfanner, E; Viti, M; Goletti, Orlando; Filipponi, Franco; Falcone, Alfredo | |
| Predictive role of a pharmacogenetic profiling in patients with advanced colorectal cancer (ACRC) treated with first-line, 5-fluorouracil/oxaliplatin chemotherapy | 1-gen-2006 | Graziano, F.; Russo, A. M.; Loupakis, F.; Canestrari, E.; Santini, D.; Catalano, V.; Ficarelli, R.; Mari, D.; Bisonni, R.; Masi, G.; Schiavon, G.; Safina, V.; Maltese, P.; Pizzagalli, F.; Giordani, P.; Lippe, P.; Alessandrini, P.; Giustini, L.; Falcone, Alfredo; Tonini, G.; Silva, R. R.; Mattioli, R.; Menichetti, E. T.; Testa, E.; Lai, V.; Magnani, M. | |
| Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation | 1-gen-2006 | Allegrini, G; DI PAOLO, Antonello; Cerri, E; Cupini, S; Amatori, F; Masi, G; Danesi, Romano; Marcucci, L; Bocci, Guido; DEL TACCA, M; Falcone, Alfredo | |
| Sequential treatment with cisplatin (P) in combination with infusional 5-FU/LV (PFL) followed by Irinotecan (IR) + 5-FU/LV (IRFL) followed by Docetaxel (T) + 5-FU/LV (TFL) in patients (PTS) with metastatic (M) gastric carcinoma (GC): preliminary results of a phase II trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) | 1-gen-2006 | Loupakis, F.; Masi, G.; Fontana, E.; Allegrini, G.; Bursi, S.; Barbara, C.; Cerri, E.; Barletta, M. T.; Picone, V.; Mentuccia, L.; Granetto, C.; Fea, E.; Pfanner, E.; Murr, R.; Brunetti, I.; Andreuccetti, M.; Falcone, Alfredo | |
| Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) | 1-gen-2007 | Cupini, S.; Bursi, S.; Masi, G.; Loupakis, F.; Barbara, C.; Barletta, M. T.; Baldi, G. G.; Vasile, E.; Fornaro, L.; Petrini, Iacopo; Allegrini, G.; Antonuzzo, A.; DI MARSICO, R.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo | |
| Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (IR) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologico Nord-Ovest (GONO) | 1-gen-2007 | Loupakis, F.; Masi, G.; Bursi, S.; Picone, V.; Mentuccia, L.; Granetto, C.; Fea, E.; Murr, R.; Antonuzzo, A.; Falcone, Alfredo | |
| Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases | 1-gen-2007 | Masi, G.; Bursi, S.; Loupakis, F.; Barbara, C.; Brunetti, I.; Ferraldeschi, R.; Evangelista, W.; Chiara, S.; Granetto, C.; Falcone, Alfredo | |
| The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) | 1-gen-2007 | Masi, G.; Bursi, S.; Loupakis, F.; Barletta, M.; Baldi, G.; Antonuzzo, A.; Sonaglio, C.; Pfanner, E.; Petrini, Iacopo; Falcone, Alfredo | |
| Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) | 1-gen-2007 | Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; Petrini, Iacopo; Barletta, M. T.; Baldi, G. G.; Falcone, Alfredo | |
| Randomized phase III study of FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) vs FOLFIRI (irinotecan and 5FU/LV) as first-line treatment of metastatic colorectal cancer (MCRC): Subgroup and multivariate analysis | 1-gen-2007 | Falcone, Alfredo; Andreuccetti, M.; Orlandini, C.; Barbara, C.; Benedetti, G.; Evangelista, W.; Picone, V.; Chiara, S.; Granetto, C.; Masi, G. | |
| First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) | 1-gen-2007 | Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G. G.; Barletta, M. T.; Fornaro, L.; Allegrini, G.; Donati, S.; Andreuccetti, M.; Ricci, S.; Falcone, Alfredo | |
| Pharmacogenetic profiling for anti-epidermal growth factor receptor (EGFR) therapy in (pts) with refractory advanced colorectal cancer (ACRC) | 1-gen-2007 | Graziano, F.; Ruzzo, A.; Loupakis, F.; Floriani, I.; Canestrari, E.; Santini, D.; Catalano, V.; Torresi, U.; Bisonni, R.; Masi, G.; Schiavon, G.; Andreoni, F.; Maltese, P.; Giustini, L.; Falcone, Alfredo; Tonini, G.; Rulli, E.; Fontana, A.; Mari, D.; Magnani, M. | |
| First-line folfoxiri followed by R0 surgical resection of metastases in unresectable metastatic colorectal cancer (MCRC) patients (pts) | 1-gen-2007 | Masi, G.; Loupakis, F.; Bursi, S.; Barbara, C.; Barletta, M. T.; Baldi, G.; Cupini, S.; Brunetti, I.; Pfanner, E.; Lencioni, M.; DI DONATO, S.; Mentuccia, L.; Fanchini, L.; Sonaglio, C.; Fea, E.; Allegrini, G.; Falcone, Alfredo | |
| Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(MCRC): Updated results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study | 1-gen-2007 | Falcone, Alfredo; Andreuccetti, M.; Ricci, S.; Orlandini, C.; Barbara, C.; Evangelista, W.; Ciuffreda, L.; Cortesi, E.; Ferraldeschi, R.; Chiara, S.; Granetto, C.; Loupakis, F.; Bursi, S.; Allegrini, G.; Masi, G. | |
| First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group | 1-gen-2007 | Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Tognarini, L.; Sonaglio, C.; Chiara, S.; Pfanner, E.; Brunetti, I.; Petrini, Iacopo; Baldi, G.; Barletta, M.; Allegrini, G.; Ricci, S.; Falcone, Alfredo | |
| Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line folfoxiri followed by r0 surgical resection of metastases | 1-gen-2007 | Masi, G.; Bursi, S.; Loupakis, F.; Barletta, M.; Barbara, C.; Vasile, E.; Cupini, S.; Brunetti, I.; Pfanner, E.; DI DONATO, S.; Dauria, G.; Fanchini, L.; Chiara, S.; Granetto, C.; Falcone, Alfredo | |
| Pegfilgrastim to support chop-r chemotherapy administered every 14 days in the patients (pts) with aggressive b-cell non-hodgkin’s lymphoma (NHL) | 1-gen-2007 | Capochiani, E.; Cupini, S.; Loupakis, F.; Vasile, E.; Fontana, A.; Barbara, C.; Bursi, S.; Landi, L.; Coltelli, L.; Safina, V.; Barletta, M. T.; Baldi, G. G.; Giuntini, N.; LO DICO, M.; Mazzoni, E.; Masi, G.; Falcone, Alfredo | |
| Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) | 1-gen-2007 | Cupini, S.; Bursi, S.; Masi, G.; Loupakis, F.; Barbara, C.; Fornaro, L.; Allegrini, G.; DI MARSICO, R.; Andreuccetti, M.; Falcone, Alfredo |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile